Bacteriophage therapy: a regulatory perspective
The DOI matches its Crossref record.
Abstract
Despite the recognized problem of antibiotic multidrug resistance, very few antibacterial agents with new mechanisms of action are under development. Bacteriophage therapy could offer one alternative strategy to mitigate this challenge. Although widely used throughout the 20th century in Eastern Europe and the former Soviet Union, this potential therapy has not yet been investigated according to rigorous scientific standards. This paper reports on a multistakeholder meeting held at the EMA, which outlined the existing regulatory framework to which such therapy should adhere and reviewed the current obstacles and shortcomings in scientific development for bacteriophage therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Hypervirulent Klebsiella pneumoniae
Russo, T. A., & Marr, C. M. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00001-19 · Cited by 1,311
Alternatives to Conventional Antibiotics in the Era of Antimicrobial Resistance
Ghosh, C., Sarkar, P., Issa, R., & Haldar, J. (2019) · Trends in Microbiology · doi:10.1016/j.tim.2018.12.010 · Cited by 661
Considerations for the Use of Phage Therapy in Clinical Practice
Suh, G. A., Lodise, T. P., Tamma, P. D., Knisely, J. M., Alexander, J., Aslam, S., Barton, K. D., Bizzell, E., Totten, K. M. C., Campbell, J. L., et al. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02071-21 · Cited by 378
Bacteriophage Therapy: Clinical Trials and Regulatory Hurdles
Furfaro, L. L., Payne, M. S., & Chang, B. J. (2018) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2018.00376 · Cited by 362
Fighting Pathogenic Bacteria on Two Fronts: Phages and Antibiotics as Combined Strategy
Tagliaferri, T. L., Jansen, M., & Horz, H.-P. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00022 · Cited by 345
Current challenges and future opportunities of phage therapy
Pires, D. P., Costa, A. R., Pinto, G., Meneses, L., & Azeredo, J. (2020) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuaa017 · Cited by 340
Considerations and Caveats in Combating ESKAPE Pathogens against Nosocomial Infections
Ma, Y., Wang, C., Li, Y., Li, J., Wan, Q., Chen, J., Tay, F. R., & Niu, L. (2020) · Advanced Science · doi:10.1002/advs.201901872 · Cited by 314
Jurczak-Kurek, A., Gąsior, T., Nejman-Faleńczyk, B., Bloch, S., Dydecka, A., Topka, G., Necel, A., Jakubowska-Deredas, M., Narajczyk, M., Richert, M., et al. (2016) · Scientific Reports · doi:10.1038/srep34338 · Cited by 303
Belizário, J. E., & Faintuch, J. (2018) · Experientia Supplementum · doi:10.1007/978-3-319-74932-7_13 · Cited by 255
Phages and their potential to modulate the microbiome and immunity
Federici, S., Nobs, S. P., & Elinav, E. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00532-4 · Cited by 222
Bacteriophage Therapy: Discovery, Development, and FDA Approval Pathways
Niazi, S. K. (2025) · Pharmaceuticals · doi:10.3390/ph18081115 · Cited by 56
Bacteriophages as Targeted Therapeutic Vehicles: Challenges and Opportunities
Venkataraman, S., Shahgolzari, M., Yavari, A., & Hefferon, K. (2025) · Bioengineering · doi:10.3390/bioengineering12050469 · Cited by 38
The applications of animal models in phage therapy: An update
Mehmood Khan, F., Manohar, P., Singh Gondil, V., Mehra, N., Kayode Oyejobi, G., Odiwuor, N., Ahmad, T., & Huang, G. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2175519 · Cited by 32
Mutalik, V. K., & Arkin, A. P. (2022) · iScience · doi:10.1016/j.isci.2022.104121 · Cited by 32
Metadata
- Authors
- Pelfrene, E., Willebrand, E., Cavaleiro Sanches, A., Sebris, Z., & Cavaleri, M.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-04-10
- Volume
- 71
- Issue
- 8
- Pages
- 2071-2074
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2313964749
- Cited by
- 133
- References
- 0
- FWCI
- 11.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.